Regeneron Pharmaceuticals, Inc. (REGN)
Company Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.
The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Country | United States |
Founded | 1988 |
IPO Date | Apr 2, 1991 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 13,450 |
CEO | Dr. Leonard S. Schleifer M.D., Ph.D. |
Contact Details
Address: 777 Old Saw Mill River Road Tarrytown, New York 10591 United States | |
Phone | (914) 847-7000 |
Website | regeneron.com |
Stock Details
Ticker Symbol | REGN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000872589 |
CUSIP Number | 75886F107 |
ISIN Number | US75886F1075 |
Employer ID | 13-3444607 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Co-Chairman |
Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer and Co-Chairman |
Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research |
Daniel P. Van Plew | Executive Vice President and GM of Industrial Operations and Product Supply |
Marion E. McCourt | Executive Vice President of Commercial |
Christopher R. Fenimore CPA | Senior Vice President of Finance and Chief Financial Officer |
Patrice Gilooly | Senior Vice President of Quality Assurance and Operations |
Bob McCowan | Senior Vice President of IT and Chief Information Officer |
Ryan Crowe | Senior Vice President of Investor Relations and Strategic Analysis |
Joseph J. LaRosa | Executive Vice President, General Counsel and Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 14, 2024 | 144 | Filing |
Mar 1, 2024 | 144 | Filing |
Feb 26, 2024 | 144 | Filing |
Feb 26, 2024 | 144 | Filing |
Feb 26, 2024 | 144 | Filing |
Feb 23, 2024 | 144 | Filing |
Feb 22, 2024 | 144 | Filing |
Feb 22, 2024 | 144 | Filing |
Feb 14, 2024 | 144 | Filing |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |